Preventive effects of chebulic acid isolated from Terminalia chebula ...

574 H.-S. Lee et al. / Journal of Ethnopharmacology 131 (2010) 567–574
Calcutt, N.A., Cooper, M.E., Kern, T.S., Schmidt, A.M., 2009. Therapies for
hyperglycaemia-induced diabetic complications: from animal models to clinical
trials. Nature Reviews Drug Discovery 8, 417–429.
Choi, S.Y., Jung, S.H., Lee, H.S., Park, K.W., Yun, B.S., Lee, K.W., 2008. Glycation
inhibitory activity and the identification of an active compound in Plantago
asiatica extract. Phytotherapy Research 22, 323–329.
Cohen, J.D., 2007. Overview of physiology, vascular biology, and mechanisms of
hypertension. Journal of Managed Care Pharmacy 13, S6–S8.
Hiraoka, M, Nitta, N., Nagai, M., Shimokado, K., Yoshida, M., 2004. MCP-1-induced
enhancement of THP-1 adhesion to vascular endothelium was modulated
by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2dependent
pathway. Life Science 75, 1333–1341.
Huijberts, M.S., Wolffenbuttel, B.H., Boudier, H.A., Crijns, F.R., Kruseman, A.C.,
Poitevin, P., Levy, B.I., 1993. Aminoguanidine treatment increases elasticity and
decreases fluid filtration of large arteries from diabetic rats. Journal of Clinical
Investigation 92, 1407–1411.
Jay, D., Hitomi, H., Griendling, K.K., 2006. Oxidative stress and diabetic cardiovascular
complications. Free Radical Biology and Medicine 40, 183–192.
Juang, L.J., Sheu, S.J., Lin, T.C., 2004. Determination of hydrolyzable tannins
in the fruit of Terminalia chebula Retz. by high-performance liquid chromatography
and capillary electrophoresis. Journal of Separation Science 27,
718–724.
Kazakoff, P.W., McGuire, T.R., Hoie, E.B., Cano, M., Iversen, P.L., 1995. An in vitro
model for endothelial permeability: assessment of monolayer integrity. In Vitro
Cellular and Developmental Biology: Animal 31, 846–852.
Laakso, M., Kuusisto, J., 1996. Epidemiological evidence for the association of
hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent
diabetes mellitus. Annals of Medicine 28, 415–418.
Lee, H.S., Jung, S.H., Yun, B.S., Lee, K.W., 2007. Isolation of chebulic acid from Terminalia
chebula Retz. and its antioxidant effect in isolated rat hepatocytes. Archives
of Toxicology 81, 211–218.
Lee, K.-W., Mossine, V., Ortwerth, B.J., 1998. The relative ability of glucose and ascorbate
to glycate and crosslink lens proteins in vitro. Experimental Eye Research
67, 95–104.
Lehman, T.D., Ortwerth, B.J., 2001. Inhibitors of advanced glycation end productassociated
protein cross-linking. Biochimica et Biophysica Acta (BBA): Molecular
Basis of Disease 1535, 110–119.
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. Journal of Immunological
Methods 65, 55–63.
Murali, Y.K., Anand, P., Tandon, V., Singh, R., Chandra, R., Murthy, P.S., 2007.
Long-term effects of Terminalia chebula Retz. on hyperglycemia and associated
hyperlipidemia, tissue glycogen content and in vitro release of insulin in streptozotocin
induced diabetic rats. Experimental Clinical Endocrinology & Diabetes
115, 641–646.
Naik, G.H., Priyadarsini, K.I., Bhagirathi, R.G., Mishra, B., Mishra, K.P., Banavalikar,
M.M., Mohan, H., 2005. In vitro antioxidant studies and free radical reactions of
triphala, an ayurvedic formulation and its constituents. Phytotherapy Research
19, 582–586.
Ohashi, S., Abe, H., Takahashi, T., Yamamoto, Y., Takeuchi, M., Arai, H., Nagata, K., Kita,
T., Okamoto, H., Yamamoto, H., Doi, T., 2004. Advanced glycation end products
increase collagen-specific chaperone protein in mouse diabetic nephropathy.
Journal of Biological Chemistry 279, 19816–19823.
Rao, N.K., Nammi, S., 2006. Antidiabetic and renoprotective effects of the chloroform
extract of Terminalia chebula Retz. seeds in streptozotocin-induced diabetic rats.
BMC Complementary and Alternative Medicine 6, 17–22.
Renier, G., Mamputu, J.C., Serri, O., 2003. Benefits of gliclazide in the atherosclerotic
process: decrease in monocyte adhesion to endothelial cells. Metabolism 52,
13–18.
Roffey, B.W.C., Atwal, A.S., Johns, T., Kubow, S., 2007. Water extracts from Momordica
charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose
cells. Journal of Ethnopharmacology 112, 77–84.
Sabu, M.C., Kuttan, R., 2002. Anti-diabetic activity of medicinal plants and its relationship
with their antioxidant property. Journal of Ethnopharmacology 81,
155–160.
Saleem, A., Husheem, M., Harkonen, P., Pihlaja, K., 2002. Inhibition of cancer cell
growth by crude extract and the phenolics of Terminalia chebula Retz. fruit.
Journal of Ethnopharmacology 81, 327–336.
Saleh, H.H., Rashad, H., Khafaga, S., 1952. Pharmacological action of Terminalia
chebula. Journal of the Egyptian Medical Association 35, 763–771.
Sato, Y., Oketani, H., Singyouchi, K., Ohtsubo, T., Kihara, M., Shibata, H., Higuti,
T., 1997. Extraction and purification of effective antimicrobial constituents of
Terminalia chebula Rets. against methicillin-resistant Staphylococcus aureus. Biological
and Pharmaceutical Bulletin 20, 401–404.
Shaila, H.P., Udupa, S.L., Udupa, A.L., 1998. Hypolipidemic activity of three indigenous
drugs in experimentally induced atherosclerosis. International Journal of
Cardiology 67, 119–124.
Shin, T.Y., Jeong, H.J., Kim, D.K., Kim, S.H., Lee, J.K., Chae, B.S., Kim, J.H., Kang, H.W., Lee,
C.M., Lee, K.C., Park, S.T., Lee, E.J., Lim, J.P., Kim, H.M., Lee, Y.M., 2001. Inhibitory
action of water soluble fraction of Terminalia chebula on systemic and local
anaphylaxis. Journal of Ethnopharmacology 74, 133–140.
Shukla, S.K., Chaudhary, P., Prem Kumar, I., Afrin, F., Puri, S.C., Qazi, G.N., Sharma,
R.K., 2006. Cytotoxic and radioprotective effects of Podophyllum hexandrum.
Environmental Toxicology and Pharmacology 22, 113–120.
Takeuchi, M., Bucala, R., Suzuki, T., Ohkubo, T., Yamazaki, M., Koike, T., Kameda, Y.,
Makita, Z., 2000. Neurotoxicity of advanced glycation end-products for cultured
cortical neurons. Journal of Neuropathology and Experimental Neurology 59,
1094–1105.
Takeuchi, M., Yamagishi, S., 2004. Alternative routes for the formation of
glyceraldehyde-derived AGEs (TAGE) in vivo. Medical Hypotheses 63, 453–455.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) Study Research Group, 2005. Intensive
diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
New England Journal of Medicine 353, 2643–2653.
Thornalley, P.J., 2003. Use of aminoguanidine (Pimagedine) to prevent the formation
of advanced glycation endproducts. Archives of Biochemistry and Biophysics
419, 31–40.
Twigg, S.M., Cao, Z., McLennan, S.V., Burns, W.C., Brammar, G., Forbes, J.M., Cooper,
M.E., 2002. Renal connective tissue growth factor induction in experimental
diabetes is prevented by aminoguanidine. Endocrinology 143, 4907–4915.
Wautier, M.-P., Chappey, O., Corda, S., Stern, D.M., Schmidt, A.M., Wautier, J.-L., 2001.
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression
via RAGE. American Journal of Physiology, Endocrinology and Metabolism
280, E685–E694.
Wendt, T., Tanji, N., Guo, J., Hudson, B.I., Bierhaus, A., Ramasamy, R., Arnold, B.,
Nawroth, P.P., Yan, S.F., D’Agati, V., Schmidt, A.M., 2003. Glucose, glycation,
and RAGE: implications for amplification of cellular dysfunction in diabetic
nephropathy. Journal of the American Society of Nephrology 14, 1383–1395.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications Research Group, 2003. Sustained effect
of intensive treatment of type 1 diabetes mellitus on development and progression
of diabetic nephropathy: the Epidemiology of Diabetes Interventions and
Complications (EDIC) Study. Journal of the American Medical Association 290,
2159–2167.
Xu, S.W., Howat, S.L., Renzoni, E.A., Holmes, A., Pearson, J.D., Dashwood, M.R., Bou-
Gharios, G., Denton, C.P., du Bois, R.M., Black, C.M., Leask, A., Abraham, D.J., 2004.
Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts
through MEK/ERK. Journal of Biological Chemistry 279, 23098–23103.
Yamagishi, S., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., Takeuchi, M., Makita, Z.,
2002. Advanced glycation end product-induced apoptosis and overexpression
of vascular endothelial growth factor and monocyte chemoattractant protein-
1 in human-cultured mesangial cells. Journal of Biological Chemistry 277,
20309–20315.
Yamagishi, S., Nakamura, K., Matsui, T., Ueda, S., Fukami, K., Okuda, S., 2008. Agents
that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)oxidative
stress system: a novel therapeutic strategy for diabetic vascular
complications. Expert Opinion on Investigational Drugs 17, 983–996.
Zannad, F., 2008. Implications of the ADVANCE study for clinical practice. Journal of
Hypertension 26 (Suppl. 3), S31–S34.